Aclarion Raises $4.7 Million in Registered Direct Stock Offering
TL;DR
Aclarion, Inc. sold 506,803 shares at $9.25/share, raising $4.7 million in a registered direct offering, providing investors with potential financial growth.
Aclarion's Nociscan utilizes MRS, signal processing, biomarkers, and AI algorithms to pinpoint sources of chronic low back pain for precise treatment optimization.
Aclarion's technology enhances patient care by aiding physicians in identifying the exact location of chronic low back pain, leading to personalized and effective treatment plans.
Aclarion's innovative Nociscan platform blends medical science with AI to revolutionize chronic low back pain diagnosis, showcasing the future of healthcare technology.
Found this article helpful?
Share it with your network and spread the knowledge!
Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnostics, announced a registered direct offering of 506,803 shares of common stock at $9.25 per share. The transaction is expected to generate approximately $4.7 million in gross proceeds for the company.
The funding will be strategically allocated across multiple critical business areas, including market development, clinical evidence generation, product development and quality enhancement, and general corporate support. By securing this capital, Aclarion aims to advance its innovative Nociscan platform, which leverages magnetic resonance spectroscopy and artificial intelligence to help physicians identify the source of chronic low back pain.
Dawson James Securities, Inc. is serving as the sole placement agent for the offering. The transaction will be conducted pursuant to an existing shelf registration statement that was previously declared effective by the Securities and Exchange Commission.
The offering represents a significant milestone for Aclarion, providing financial resources to continue developing its unique healthcare technology solution. By focusing on noninvasive diagnostic tools that utilize advanced signal processing techniques and biomarkers, the company is positioned to potentially transform chronic pain diagnosis and treatment strategies.
The stock offering is subject to customary closing conditions and is anticipated to be completed by January 31, 2025. This financial move underscores Aclarion's commitment to innovation in the healthcare technology sector.
Curated from NewMediaWire
